Loading clinical trials...
Loading clinical trials...
Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer
Conditions
Interventions
Erlotinib
Locations
1
China
Guangzhou medical university
Guanzhou, Guangdong, China
Start Date
August 1, 2013
Primary Completion Date
August 1, 2018
Completion Date
December 1, 2018
Last Updated
February 12, 2015
NCT06305754
NCT07486219
NCT05098132
NCT06731413
NCT04585750
NCT05987644
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions